Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | September 2009 |
| End Date: | January 2022 |
| Contact: | John M. DeWitt, MD |
| Email: | jodewitt@iu.edu |
| Phone: | 317-944-5392 |
The purpose of this study is to track outcomes and complications of patients at IUMC referred
by physicians for EUS-guided pancreatic cyst ablation. This information is essential in order
to disseminate future published information to physicians about this technique. A database
will be created to track these patients undergoing an already scheduled/planned procedure.
Phone calls at selected intervals will be made following the procedure to track any
complications that occur
by physicians for EUS-guided pancreatic cyst ablation. This information is essential in order
to disseminate future published information to physicians about this technique. A database
will be created to track these patients undergoing an already scheduled/planned procedure.
Phone calls at selected intervals will be made following the procedure to track any
complications that occur
Pancreatic cysts represent a wide spectrum of lesions. Many cysts are uniformly benign
(pseudocysts) or have negligible malignant potential (serous cystadenomas). However, others
represent premalignant (i.e. intraductal papillary mucinous neoplasms (IPMNs) or mucinous
cystadenomas [MCN]), or malignant (i.e. invasive IPMNs or mucinous cystadenocarcinomas)
tumors. Management of pancreatic cysts is challenging but surgery is generally recommended
for cysts that are symptomatic, premalignant (except possibly branch duct IPMNs) or
demonstrate malignancy by imaging features and/or biopsy. However, even in experienced
hospitals, surgical resection or enucleation of pancreatic cystic tumors is associated with
significant perioperative morbidity and mortality rates of 20-40% and up to 2%, respectively.
(pseudocysts) or have negligible malignant potential (serous cystadenomas). However, others
represent premalignant (i.e. intraductal papillary mucinous neoplasms (IPMNs) or mucinous
cystadenomas [MCN]), or malignant (i.e. invasive IPMNs or mucinous cystadenocarcinomas)
tumors. Management of pancreatic cysts is challenging but surgery is generally recommended
for cysts that are symptomatic, premalignant (except possibly branch duct IPMNs) or
demonstrate malignancy by imaging features and/or biopsy. However, even in experienced
hospitals, surgical resection or enucleation of pancreatic cystic tumors is associated with
significant perioperative morbidity and mortality rates of 20-40% and up to 2%, respectively.
Inclusion Criteria:
1. Patients referred between January 2009 and February 2016 to EUS at IUMC for pancreatic
cyst ablation and with no contraindications for anticipated safe and successful
performance of the procedure.
2. Patient at least 18 years of age.
Exclusion Criteria:
1. Investigator deems cyst does not meet safety or need for cyst ablation.
2. Subject not competent to sign consent
We found this trial at
1
site
550 University Boulevard
Indianapolis, Indiana 46202
Indianapolis, Indiana 46202
Principal Investigator: John M DeWitt, MD
Phone: 317-944-5392
Click here to add this to my saved trials
